Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start" with more than 3,500 healthcare ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

The results of the present study, which is the first to demonstrate the effects of NAC on lung function, support a role for NAC as an anti-inflammatory agent in the treatment of COPD exacerbations.

30 in The BMJ. William B. Feldman, MD, MPH, from Brigham and Women’s Hospital in Boston, and colleagues compared the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice-daily ...

By Dr. Chinta Sidharthan The researchers evaluated budesonide-glycopyrrolate-formoterol and ...

30 in The BMJ. William B. Feldman, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues compared the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a ...

Conclusion. In the treatment of COPD exacerbations, systemic corticosteroids improve airflow limitations, decrease treatment failure rates, decrease the risk of relapse, and may improve symptoms ...

Experts have warned that people need to be aware of a little known winter illness that can cause 'severe disease' for people ...

It's the first ever biologic medicine for COPD in either country. Specifically, the drug is indicated in both countries as an add-on treatment for patients with inadequately controlled COPD and an ...